LIBERATE Trial in COVID-19

Exclusion Criteria

• •1. Any of the following contraindications to ibuprofen:
• •* A known hypersensitivity to ibuprofen or any other constituent of the medicinal product;
• •* Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs);
• •* Patients with a history of, or existing gastrointestinal ulceration/perforation or bleeding, including that associated with NSAIDs;
• •* Patients with severe hepatic failure;
• •* Patients with acute renal failure;
• •* Patients with severe heart failure.
• •2. Participation in any other investigational drug products less than 30 days prior to study enrolment;
• •3. Glasgow Coma Score \< 12;
• •4. Patients who cannot swallow oral capsules;
• •5. Pregnant or lactating women;
• •6. Any medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial.